Recombinant Human Antibody (J16) is capable of binding to PCSK9, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-PCSK9 mAb and CH1-3 region of human IgG and a light chain (LC) encoding VL from anti-PCSK9 proteins mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody, J16, potently inhibit PCSK9 binding to the LDLR extracellular domain and PCSK9-mediated down-regulation of LDLR in vitro.
Figure 1 PCSK9 internalization with J16.
PCSK9-488 internalization in the presence of 5F6 and J16 in HepG2 cells. Internalized human and mouse antibodies shown in blue and red, respectively. Scale bars, 10 μm.
DeVay, R. M., Yamamoto, L., Shelton, D. L., & Liang, H. (2015). Common proprotein convertase subtilisin/kexin type 9 (PCSK9) epitopes mediate multiple routes for internalization and function. PloS one, 10(4).
Figure 2 APLP2 and LDLR interactions with PCSK9 and their regulation of PCSK9 function.
Western blot showing APLP2, PCSK9, orTransferrin receptor (TFNR) levels in input fraction (I), IC or J16 immunoprecipitated samples (IP Ab.) in the absence or presence of 5F6 Fab or 12E3 Fab.
DeVay, R. M., Yamamoto, L., Shelton, D. L., & Liang, H. (2015). Common proprotein convertase subtilisin/kexin type 9 (PCSK9) epitopes mediate multiple routes for internalization and function. PloS one, 10(4).
Figure 3 Characterization of PCSK9 internalization and subsequent J16 or LDLR lysosomal trafficking in HepG2 cells.
Colocalization of LDLR (green) with lysosomes (Lamp2; red) in DAPI (blue)-stained cells in the presence of PCSK9IC or PCSK9J16. Scale bars, 10 μm.
DeVay, R. M., Shelton, D. L., & Liang, H. (2013). Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). Journal of Biological Chemistry, 288(15), 10805-10818.
Figure 4 Identification and biochemical characterization of interactions between PCSK9 and members of the amyloid precursor protein family.
Western blots showing APLP2, APP, PCSK9-His, or TFNR levels in input (I), IC IP, or J16 IP samples. co-IPs were performed at pH 6.0 using HepG2 lysates.
DeVay, R. M., Shelton, D. L., & Liang, H. (2013). Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). Journal of Biological Chemistry, 288(15), 10805-10818.
Figure 5 Recombinant PCSK9, APLP2, and LDLR form a trimeric complex in vitro.
ELISA of APLP2-PCSK9-LDLR complex with 4 μg/ml PCSK9 and 12 μg/ml IC, J16, or 5F6.
DeVay, R. M., Shelton, D. L., & Liang, H. (2013). Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). Journal of Biological Chemistry, 288(15), 10805-10818.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H10 | Anti-Human PCSK9 Recombinant Antibody (Bococizumab) | WB, FC, IP, ELISA, Neut, FuncS, IF | IgG2 - kappa |
TAB-0957CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (h7F8) | ELISA | Humanized antibody |
TAB-0958CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (h7F8ml2) | ELISA | Humanized antibody |
TAB-0957CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (h7F8) | ELISA | Humanized antibody |
TAB-0958CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (h7F8ml2) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-294 | Human Anti-PCSK9 Recombinant Antibody (clone mAb1) | WB, Block, FuncS | Human IgG |
HPAB-0234-YC | Mouse Anti-PCSK9 Recombinant Antibody (HPAB-0234-YC) | ELISA, FuncS | Mouse IgG |
HPAB-0051-FY | Human Anti-PCSK9 Recombinant Antibody (HPAB-0051-FY) | Inhib, ELISA | Human IgG2, κ |
HPAB-0141-FY | Human Anti-PCSK9 Recombinant Antibody (clone YW508.20.33) | FuncS, In vivo | Human IgG1 |
HPAB-0152-FY | Mouse Anti-PCSK9 Recombinant Antibody (HPAB-0152-FY) | ELISA | Mouse IgG, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBL-294 | Human Anti-PCSK9 Recombinant Antibody (clone mAb1); scFv Fragment | WB, Block, FuncS | Human scFv |
PSBC-505 | Human Anti-PCSK9 Recombinant Antibody (clone 5E11); scFv Fragment | WB, IP, ELISA, IF, Inhib | Human scFv |
HPAB-0479-YJ-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0479-YJ-S(P)) | ELISA, Inhib, FuncS | Human scFv |
HPAB-0480-YJ-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0480-YJ-S(P)) | ELISA, Inhib, FuncS | Human scFv |
HPAB-0724YY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0724YY-S(P)) | ELISA | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0953CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0953CL) | ELISA | Human IgG1 |
TAB-0959CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0959CL) | ELISA, FC | Human antibody |
TAB-0953CL-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (TAB-0953CL-S(P)) | ELISA | Human scFv |
TAB-0954CL-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (TAB-0954CL-S(P)) | WB | Human scFv |
TAB-0955CL-S(P) | Mouse Anti-PCSK9 Recombinant Antibody; scFv Fragment (TAB-0955CL-S(P)) | WB | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0956CL | Anti-Human PCSK9 Recombinant Antibody (m7F8) | ELISA | |
TAB-0960CL | Anti-Human PCSK9 Recombinant Antibody (Ab1) | ELISA | Rabbit mAb |
TAB-0956CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (m7F8) | ELISA | |
TAB-0960CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (Ab1) | ELISA | Rabbit mAb |
TAB-0956CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (m7F8) | ELISA |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBC-196 | Human Anti-PCSK9 Recombinant Antibody (clone J16); scFv Fragment | ELISA | Human scFv |
HPAB-N0377-YC-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-N0377-YC-F(E)) | FC, FuncS | Human Fab |
HPAB-667-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-667-FY-F(E)) | Inhib | Human Fab |
HPAB-668-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-668-FY-F(E)) | Inhib | Human Fab |
HPAB-2454LY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-2454LY-F(E)) | ELISA, Inhib | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0080CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKE2) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0081CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKF8) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0082CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKG1) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0083CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (P1.70) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0084CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKE1) | FuncS, Inhib, FC, WB | Single domain antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1826CQ | Recombinant Human Anti-PCSK9 Antibody, Unconjugated | Neut | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2618 | Hi-Affi™ Recombinant Rabbit Anti-PCSK9 Monoclonal Antibody (DS2618AB) | WB | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-758 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Lodelcizumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
AFC-TAB-H10 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS | ADCC enhanced antibody |
AFC-TAB-H59 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Ralpancizumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-H31 | Afuco™ Anti-PCSK9 Recombinant Antibody (AFC-TAB-H31), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | Human IgG1, λ |
There are currently no Customer reviews or questions for PABC-196. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.